Delivery Order SPE2DB24D1021-SPE2DB25FEZAD
- Not listed
- The Defense Logistics Agency awarded a $18,121.68 delivery order to AmerisourceBergen Drug Corp on July 11, 2025, for the supply of DUPIXENT 300 mg/2 ml pen injectable medication in 2 ml quantities. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 14, 2025. The contract is being performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, and represents a child delivery order under the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 ml pen injectors, valued at $6,777.99, with an ultimate completion date of August 15, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a continuation of the company's ongoing pharmaceutical supply relationship with the federal government. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $8,632.83 to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML pen injectors (2ML). The contract, executed on August 28, 2025, with completion targeted for August 29, 2025, represents a firm fixed-price delivery order with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfilled this order through competitive procurement processes. This...
- The Defense Logistics Agency awarded a $3,418.92 firm fixed-price delivery order to AmerisourceBergen Drug Corp for supply of DUPIXENT 200 mg/1.14 ml pen injectors, with an ultimate completion date of August 12, 2025. This non-set-aside award represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA Troop Support Medical. The product will be performed at the contractor's location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML pen injectors valued at $7,550.30 under a firm fixed price contract. The award was made on July 21, 2025, with an ultimate completion date of July 22, 2025, and represents a non-set-aside competitive award. AmerisourceBergen will perform this work at its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $5,001.99 firm fixed-price delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 mL pens on July 18, 2025, with an ultimate completion date of July 21, 2025. This non-set-aside contract represents a delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and running through December 2026. The pharmaceutical product will be delivered to...
- The Defense Logistics Agency awarded a $14,397.15 delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 ml pen auto-injectors. The contract, finalized on August 12, 2025, with completion targeted for August 13, 2025, utilizes firm fixed pricing with no set-aside designation, indicating competitive award through open solicitation. Performance will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, the company's headquarters. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of DUPIXENT 300 mg/2 mL pen injections with a ceiling value of $2,007.95. This is a firm fixed-price delivery order with no set-aside designation, issued under competitive procedures. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 26, 2025. As a child contract, this delivery...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $20,072.57 on August 7, 2025, for the supply of DUPIXENT 300 mg/2 ml pen injectors (2 ml units). The contract employs firm fixed pricing with no set-aside designation, indicating competitive award. Performance will be executed at AmerisourceBergen's corporate facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 8, 2025. This delivery order is a child contract under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML pen injections with a ceiling value of $4,147.68 under a firm fixed price contract type. The award was made on September 3, 2025, with an ultimate completion date of September 4, 2025, with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location. This delivery order represents a child...
- SPE2DB24D1021Indefinite Delivery Contract
- SPE2DB24D1021-SPE2DB25FEZADDelivery Order
The Defense Logistics Agency awarded a $22,738.07 firm fixed price delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML pen injectors (2 ML). The contract was executed on July 29, 2025, with an ultimate completion date of July 30, 2025, and is being fulfilled at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a non-set-aside, competitively awarded contract issued under the company's existing Indefinite Delivery Contract vehicle with DLA Troop Support Medical. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, holds a significant prime IDC valued at $999,999,999.00 running through December 2026 that serves as the foundation for this delivery order. The company supplies a comprehensive range of pharmaceutical products to support military healthcare programs and federal medical procurement needs, including specialty medications, brand-name and generic drugs, and medical devices. This particular order for DUPIXENT, a biologic treatment for eczema and other conditions, reflects the breadth of specialty pharmaceutical commodities that AmerisourceBergen provides to support Defense Health Agency and other government healthcare systems through its flexible contract vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $22.7k | 7/29/25 |